Get started
Author

Nurit Horesh

Does Gender Matter in Non-Hodgkin Lymphoma? Differences in Epidemiology, Clinical Behavior, and Therapy
2014 · Nurit Horesh, Netanel A. Horowitz · Rambam Maimonides Medical Journal · 87
PDF
The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors
2021 · Ali Khateb, Anagha Deshpande, et al. · Nature Communications · 62
PDF
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies
2021 · Ronit Gurion, Uri Rozovski, et al. · Haematologica · 58
PDF
Attenuated humoral immune response following anti‐SARS‐CoV ‐2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis
2021 · Neta Schiller Salton, Moran Szwarcwort, et al. · American Journal of Hematology · 21
PDF
Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma
2026 · Danny Luan, Ori Ben Valid, et al. · Blood · 12
PDF
Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma—a real-world multicenter retrospective cohort study
2023 · Tamar Berger, Tzippy Shochat, et al. · Annals of Hematology · 8
Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3‐ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission
2020 · Yishai Ofran, Ronit Leiba, et al. · European Journal Of Haematology · 5
Obinutuzumab Maintenance in Follicular Lymphoma Is Associated With Better Progression Free Survival and Comparable Toxicity
2026 · Renana Robinson, Tamar Berger, et al. · European Journal Of Haematology · 1
In Patients with Acute Myeloid Leukemia, Hidac Administered on Days 1, 2 and 3 of Consolidation Course Is As Efficacious As Hidac Given on Days 1, 3 and 5, but Is Better Tolerated
2021 · Baher Krayem, Avraham Frisch, et al. · Blood · 1
Single agent oral selinexor as a key to potential cure in refractory diffuse large B-cell lymphoma: case report and literature review.
2021 · Nurit Horesh, Michal Weiler-Sagie, et al. · PubMed Central · 1
RNF5 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors
2020 · Ali Khateb, Anagha Deshpande, et al. · Blood · 1
Ixazomib, pomalidomide and dexamethasone in triple-class exposed multiple myeloma patients - a phase II study
2026 · Tamir Shragai, Noa Lavi, et al. · Haematologica
PDF
Author Correction: The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors
2026 · Ali Khateb, Anagha Deshpande, et al. · Nature Communications
PDF
Platelet and Fibrinogen Dynamics After CAR ‐T Cell Therapy in Relapsed/Refractory B‐Cell Lymphoma May Predict ICANS Onset
2026 · Hazim Khatib, Amit Parizat, et al. · European Journal Of Haematology
Pulmonary function tests performed prior to CAR-T cell administration could be instrumental in predicting post-treatment pulmonary toxicity: A single-arm prospective study
2025 · Ofrat Beyar-Katz, Elias Maroun, et al. · Blood
PDF
531 | Adjustment of Chemotherapy Duration According to Peripheral Blood or Bone Marrow Minimal Residual Disease Status in Patients With Follicular Lymphoma
2025 · U. Abadi, N. Dally, et al. · Hematological Oncology
PDF
HiDAC Consolidation in AML : Comparable Outcomes With Reduced Toxicity Using a Three‐Day Schedule ( HiDAC ‐123)
2025 · Baher Krayem, Nurit Horesh, et al. · European Journal Of Haematology
PDF
Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma
2024 · Hazim Khatib, Amit Parizat, et al. · Blood
Similar Safety Profile for Rituximab and Obinutuzumab as Maintenance for Follicular Lymphoma: Evidence From a Real-World Multicenter Retrospective Cohort Study
2024 · Odil Giladi, Tamar Berger, et al. · Clinical Lymphoma Myeloma & Leukemia
IBCL-236 Similar Safety Profile for Rituximab and Obinutuzumab as Maintenance for Follicular Lymphoma: Evidence From a Real-World Multicenter Retrospective Cohort Study
2024 · Odil Giladi, Tamar Berger, et al. · Clinical Lymphoma Myeloma & Leukemia
Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia
2022 · Shimrit Harlev, Nashwa Fadaos, et al. · Blood
Obinutuzumab Versus Rituximab Based First-Line Chemoimmunotherapy for Follicular Lymphoma - a Real-World Multicenter Retrospective Cohort Study
2022 · Tamar Berger, Tzippy Shochat, et al. · Blood
P1584: Cellular Immune Response to the Bnt162b2 Vaccine in Lymphoma Patients
2022 · R. Gurion, U. Rozovski, et al. · HemaSphere
NPM1 Quantitative Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia Allows More Precise Selection of Patients for Allogeneic Stem Cell Transplantation without Affecting Their Survival
2019 · Yishai Ofran, Ronit Leiba, et al. · Blood
Treating Indolent Lymphoma in Older Adults: What Is the Right Way?
2015 · Nurit Horesh, Noa Lavi, et al. · Blood
Works count: 25
Citation count: 257
H-index: 6
I10-index: 5
Year
Topic
Type